Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renal protective properties from podcast guests Kim Newlin, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, from the University of Colorado in Denver.
Earn 0.5 contact hours and .05 pharmacology hours from listening to podcast and completing the course components.
- Discuss the use of SGLT2 inhibitors and GLP-1 receptor agonists to treat hyperglycemia in patients with Type 2 Diabetes
- Explore data from cardiovascular outcome trials that indicate that SGLT2is & GLP-1 RAs have positive effects on reducing obesity as well as cardioprotective, renal protective, and additional weight loss benefits in persons with or without diabetes
- Kim Newlin, MSN, ANP, FPCNA
- Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of PCNA. PCNA is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 030602.